BRPI0924296A2 - composição farmacêutica para tratar do câncer compreendendo um composto conjugado de cloro e6-ácido fólico e quitosana - Google Patents

composição farmacêutica para tratar do câncer compreendendo um composto conjugado de cloro e6-ácido fólico e quitosana

Info

Publication number
BRPI0924296A2
BRPI0924296A2 BRPI0924296A BRPI0924296A BRPI0924296A2 BR PI0924296 A2 BRPI0924296 A2 BR PI0924296A2 BR PI0924296 A BRPI0924296 A BR PI0924296A BR PI0924296 A BRPI0924296 A BR PI0924296A BR PI0924296 A2 BRPI0924296 A2 BR PI0924296A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating cancer
folic acid
chitosan compound
conjugated
Prior art date
Application number
BRPI0924296A
Other languages
English (en)
Inventor
Hee Lee Eun
Jun Kim Hyo
Shin Park Kye
Original Assignee
Diatech Korea Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatech Korea Co Ltd filed Critical Diatech Korea Co Ltd
Publication of BRPI0924296A2 publication Critical patent/BRPI0924296A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/722Chitin, chitosan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0924296A 2009-04-29 2009-04-29 composição farmacêutica para tratar do câncer compreendendo um composto conjugado de cloro e6-ácido fólico e quitosana BRPI0924296A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2009/002277 WO2010126179A1 (ko) 2009-04-29 2009-04-29 클로린 e6-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BRPI0924296A2 true BRPI0924296A2 (pt) 2019-09-24

Family

ID=43032311

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924296A BRPI0924296A2 (pt) 2009-04-29 2009-04-29 composição farmacêutica para tratar do câncer compreendendo um composto conjugado de cloro e6-ácido fólico e quitosana

Country Status (6)

Country Link
US (1) US20120035180A1 (pt)
EP (1) EP2431040A1 (pt)
JP (1) JP2011518891A (pt)
CN (1) CN101977608A (pt)
BR (1) BRPI0924296A2 (pt)
WO (1) WO2010126179A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
CN106279212B (zh) * 2016-08-01 2019-06-18 康宏耀源(天津)科技有限公司 以叶酸为靶向基团的光敏药物的合成和应用
KR102173861B1 (ko) 2019-02-12 2020-11-05 한국화학연구원 약물담지용 키토산 나노섬유 복합체 및 이의 제조방법
RU2704202C1 (ru) * 2019-07-03 2019-10-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ фотодинамической терапии перевивной поверхностной солидной соединительнотканной саркомы м-1 крыс

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688721T2 (de) * 1985-04-30 1993-12-16 Nippon Petrochemicals Co Ltd Verwendung von Porphyrinderivaten bei der Entdeckung und Behandlung von Tumoren.
EP1150655B1 (de) * 1999-02-09 2003-09-17 Cognis Deutschland GmbH & Co. KG Verwendung von nanoskaligen chitosanen
GB0520436D0 (en) * 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
CN101977608A (zh) 2011-02-16
WO2010126179A1 (ko) 2010-11-04
EP2431040A1 (en) 2012-03-21
US20120035180A1 (en) 2012-02-09
JP2011518891A (ja) 2011-06-30

Similar Documents

Publication Publication Date Title
IL255097A0 (en) Antimicrobial compounds, pharmaceutical preparations containing them and their uses
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
SMT201600259B (it) Composizioni farmaceutiche antibatteriche
IL215079A (en) A pharmacological preparation containing colchicine or thiocholchicine for the treatment of a thriving disease
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
AR066564A1 (es) Una combinacion farmaceutica sinergica para el tratamiento de cancer
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1008598A2 (pt) composição farmacêutica para inalação
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BR112013011967A2 (pt) composição biodegradável para distribuição de fármaco
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP2445485A4 (en) DRUG MEDICINE
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0924296A2 (pt) composição farmacêutica para tratar do câncer compreendendo um composto conjugado de cloro e6-ácido fólico e quitosana
EP2689777A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING HEPATIC DISEASES
BR112012004701A2 (pt) compostos e composições para tratamento do câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.